

Drug Formulary Update, March 2013

Updates to the HealthPartners Drug Formularies are listed below.

Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota Care “State Programs”) Drug Formulary are listed first, and then changes for the Medicare Drug Formulary.

Commercial and Minnesota Health Care Programs

These changes are effective March 1, 2013, and apply to PreferredRx, GenericsPlusRx, and HealthPartners Minnesota Health Care Programs (Medicaid and Minnesota Care “State Programs”) Drug Formularies.

Medication	Status	Notes
Apixaban (Eliquis)	F	Apixaban has been added to all formularies. All three new anticoagulants are on formulary - apixaban (Eliquis), dabigatran (Pradaxa), and rivaroxaban (Xarelto). Apixaban and dabigatran are FDA-approved for many patients with atrial fibrillation. Rivaroxaban is FDA-approved for many patients with atrial fibrillation, and for treating and preventing deep vein thrombosis and pulmonary embolism. A more detailed discussion including choosing between these medications, contra-indications and precautions, monitoring, management of bleeding, perioperative management, and patient education is being developed.
Dabigatran (Pradaxa)	F	Prior authorization has been removed. All three new anticoagulants are on formulary - apixaban (Eliquis), dabigatran (Pradaxa), and rivaroxaban (Xarelto).
Doxycycline	F	Several new forms are being added, due to drug shortages. Doxycycline hyclate 20 mg tablet, and doxycycline monohydrate 50 mg and 100 mg capsules are being added.
Epinephrine (Auvi-Q)	F	Auvi-Q is an epinephrine pen for treating allergic reactions. Similar products on formulary include EpiPen and EpiPen Jr. Costs are similar.
Fenofibrate (Tricor) generic	F	Tricor is now generic, and step-therapy has been removed.

F, on formulary
Age, Age limits

PA, prior authorization
NF, non-formulary

ST, step-therapy

QL, Quantity Limit

Drug Formulary Update, p. 2 of 2

Medication	Status	Notes
Rivaroxaban (Xarelto)	F	Prior authorization has been removed. All three new anticoagulants are on formulary - apixaban (Eliquis), dabigatran (Pradaxa), and rivaroxaban (Xarelto).
Sildenafil (Revatio generic)	PA	Revatio is now generic, and on formulary with prior authorization. Revatio is reserved for prescribing by a pulmonologist or cardiologist, for patients with a diagnosis of pulmonary arterial hypertension in World Health Organization Group I. Tadalafil (Adcirca) remains on formulary with the same prior authorization. Revatio is considered a specialty medication, with distribution by CVS Caremark Specialty Pharmacy.

Medicare Drug Formulary

These changes are effective March 1, 2013.

Medication	Status	Notes
Apixaban (Eliquis)	T2	Apixaban has been added to formulary.
Dabigatran (Pradaxa)	T2	Prior authorization has been removed.
Epinephrine (Auvi-Q)	T2	Auvi-Q is an epinephrine pen for treating allergic reactions. Similar products on formulary include EpiPen and EpiPen Jr. Costs are similar.
Rivaroxaban (Xarelto)	T2	Prior authorization has been removed.

For Medicare: T1, covered generic T2, covered Brand T3, covered Brand T4, specialty

Formulary Information and Requests

Formulary Information is available at [HealthPartners.com/ Provider/ Pharmacy Services](http://HealthPartners.com/Provider/Pharmacy_Services), including the [Drug Formularies](#).

Pharmacy Customer Service is available to providers (physicians and pharmacies) from 8AM - 6PM CST, Monday through Friday. After hours calls are answered by our Pharmacy Benefit Manager.

- Fax - 952-853-8700 or 1-888-883-5434. Telephone - 952-883-5813 or 1-800-492-7259.
- Mail - HealthPartners Pharmacy Services, 8170 33rd Avenue S, PO Box 1309, Mpls, MN 55440.